Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2026-02-21 @ 10:09 PM
Study NCT ID:
NCT02879318
Status:
COMPLETED
Last Update Posted:
2025-03-24
First Post:
2016-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Sponsor:
Canadian Cancer Trials Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-11-07
Start Date Type:
ACTUAL
Primary Completion Date:
2020-08-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-03-14
Completion Date Type:
ACTUAL
First Submit Date:
2016-08-22
First Submit QC Date:
None
Study First Post Date:
2016-08-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-05-05
Results First Submit QC Date:
None
Results First Post Date:
2021-05-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-14
Last Update Post Date:
2025-03-24
Last Update Post Date Type:
ACTUAL